These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 38132716)

  • 1. Oral immunization with
    Shrivastava S; Agnememel AB; Ndungo E; Islam D; Liang Y; Frenck RW; Pasetti MF
    mSphere; 2024 Jan; 9(1):e0041923. PubMed ID: 38132716
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding.
    Venkatesan MM; Ballou C; Barnoy S; McNeal M; El-Khorazaty J; Frenck R; Baqar S
    PLoS One; 2021; 16(11):e0259361. PubMed ID: 34793505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.
    Barnoy S; Baqar S; Kaminski RW; Collins T; Nemelka K; Hale TL; Ranallo RT; Venkatesan MM
    Vaccine; 2011 Aug; 29(37):6371-8. PubMed ID: 21596086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study.
    Shimanovich AA; Buskirk AD; Heine SJ; Blackwelder WC; Wahid R; Kotloff KL; Pasetti MF
    Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27927680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei.
    Frenck RW; Baqar S; Alexander W; Dickey M; McNeal M; El-Khorazaty J; Baughman H; Hoeper A; Barnoy S; Suvarnapunya AE; Kaminski RW; Venkatesan MM
    Vaccine; 2018 Aug; 36(32 Pt B):4880-4889. PubMed ID: 30037478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement-mediated serum bactericidal activity of antibodies elicited by the
    Kapulu MC; Nakakana U; Sciré AS; Sarakinou E; Conti V; Rossi O; Acquaviva A; Necchi F; Obiero CW; Martin LB; Bejon P; Njuguna P; Micoli F; Podda A
    Front Immunol; 2022; 13():971866. PubMed ID: 36203568
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G.
    Clarkson KA; Frenck RW; Dickey M; Suvarnapunya AE; Chandrasekaran L; Weerts HP; Heaney CD; McNeal M; Detizio K; Parker S; Hoeper A; Bourgeois AL; Porter CK; Venkatesan MM; Kaminski RW
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32968012
    [No Abstract]   [Full Text] [Related]  

  • 8. B memory cell responses to LPS, IVP and IpaB antigen after oral vaccination with Shigella sonnei vaccine candidates WRSs2 and WRSs3.
    Venkatesan MM; Barnoy S; Frenck R; McNeal M; Baqar S
    PLoS One; 2024; 19(1):e0290987. PubMed ID: 38232106
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies Elicited by the
    Micoli F; Rossi O; Conti V; Launay O; Sciré AS; Aruta MG; Nakakana UN; Marchetti E; Rappuoli R; Saul A; Martin LB; Necchi F; Podda A
    Front Immunol; 2021; 12():671325. PubMed ID: 34017343
    [No Abstract]   [Full Text] [Related]  

  • 10. Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination.
    Cohen D; Orr N; Robin G; Slepon R; Ashkenazi S; Ashkenazi I; Shemer J
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):451-5. PubMed ID: 8807212
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Clarkson KA; Porter CK; Talaat KR; Frenck RW; Alaimo C; Martin P; Bourgeois AL; Kaminski RW
    mSphere; 2021 Aug; 6(4):e0012221. PubMed ID: 34259559
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella sonnei Vaccine Candidate, in Bangladeshi Adults and Children.
    Sarker P; Mily A; Ara A; Haque F; Maier N; Wierzba TF; Walker RI; Venkatesan MM; Raqib R
    J Infect Dis; 2021 Dec; 224(12 Suppl 2):S829-S839. PubMed ID: 34374425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput
    Nahm MH; Yu J; Weerts HP; Wenzel H; Tamilselvi CS; Chandrasekaran L; Pasetti MF; Mani S; Kaminski RW
    mSphere; 2018 Jun; 3(3):. PubMed ID: 29898979
    [No Abstract]   [Full Text] [Related]  

  • 14. Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.
    Robin G; Keisari Y; Slepon R; Ashkenazi S; Cohen D
    Vaccine; 1999 Aug; 17(23-24):3109-15. PubMed ID: 10462247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis.
    Ndungo E; Andronescu LR; Buchwald AG; Lemme-Dumit JM; Mawindo P; Kapoor N; Fairman J; Laufer MK; Pasetti MF
    Front Immunol; 2021; 12():725129. PubMed ID: 34721387
    [No Abstract]   [Full Text] [Related]  

  • 16. Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.
    Barnoy S; Jeong KI; Helm RF; Suvarnapunya AE; Ranallo RT; Tzipori S; Venkatesan MM
    Vaccine; 2010 Feb; 28(6):1642-54. PubMed ID: 19932216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial.
    McKenzie R; Walker RI; Nabors GS; Van De Verg LL; Carpenter C; Gomes G; Forbes E; Tian JH; Yang HH; Pace JL; Jackson WJ; Bourgeois AL
    Vaccine; 2006 May; 24(18):3735-45. PubMed ID: 16095766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Threshold protective levels of serum IgG to Shigella lipopolysaccharide: re-analysis of Shigella vaccine trials data.
    Cohen D; Ashkenazi S; Schneerson R; Farzam N; Bialik A; Meron-Sudai S; Asato V; Goren S; Baran TZ; Muhsen K; Gilbert PB; MacLennan CA
    Clin Microbiol Infect; 2023 Mar; 29(3):366-371. PubMed ID: 36243351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes.
    Heine SJ; Diaz-McNair J; Andar AU; Drachenberg CB; van de Verg L; Walker R; Picking WL; Pasetti MF
    J Immunol; 2014 Feb; 192(4):1630-40. PubMed ID: 24453241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine.
    Clarkson KA; Talaat KR; Alaimo C; Martin P; Bourgeois AL; Dreyer A; Porter CK; Chakraborty S; Brubaker J; Elwood D; Frölich R; DeNearing B; Weerts HP; Feijoo B; Halpern J; Sack D; Riddle MS; Fonck VG; Kaminski RW
    EBioMedicine; 2021 Apr; 66():103308. PubMed ID: 33813141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.